Skip to main content
. Author manuscript; available in PMC: 2022 Jun 15.
Published in final edited form as: Circ Cardiovasc Imaging. 2021 Jun 15;14(6):e009025. doi: 10.1161/CIRCIMAGING.121.009025

Table 3 –

Comparison of studies that image cardiac amyloidosis over time.

Study Subtype Imaging modality Study design, patient numbers Time interval between imaging Results (of statistical significance)
Meier-Ewert et al, 2011 AL, post-chemo Echo Retrospective, 55 patients 1.3 years (non-responders), 3.1 years (responders) 43% of responders & 24% of non-responders# had >1mm reduction in IVWT
Madan et al, 2012 AL, post-chemo /SCT Echo Retrospective, 148 patients 4.25 years 41% had >2mm reduction in IVWT or >20% improvement to EF
Amano et al, 2017 AL, post-chemo Echo Retrospective, 29 patients 0.65 years LV size, SVI and CI reduced and diastolic wall strain worsened in those that died compared to survivors
Salinaro et al, 2017 AL, post-chemo Echo Retrospective, 61 patients 1 year Improvement in apical/basal strain ratio and relative apical sparing in responders compared to non-responders#
Tuzovic et al, 2017 AL, post-chemo Echo Registry data, 41 patients 0.25 years No significant change in parameters
Pun et al, 2018 AL, post-chemo/SCT Echo Retrospective, 34 patients 1 year Small reduction in EF. Otherwise no significant change in parameters
Hwang et al, 2020 AL, post-chemo (26% also had SCT) Echo Retrospective: 38 patients; prospective: 34 patients 0.25, 0.5, 1 and 2 years Increase in mitral E/e’ ratio and decrease in GLS from 3–6 months in those who died/heart transplant
Solomon et al, 2018 Hereditary ATTR, post-patisiran Echo APOLLO trial sub-analysis, 126 patients 0.75 and 1.5 years Reduction in mean LV wall thickness, reduced GLS and increased cardiac output in patisiran group compared to placebo
Zadok et al, 2020 AL and ATTR pre-diagnosis Echo Retrospective, 42 AL and 33 ATTR Upto 3 years before diagnosis Increased wall thickening, diastolic dysfunction present >3 years, significant diastolic dysfunction and LV deterioration seen between 1–3 years before diagnosis
Martinez-Naharro et al, 2019 AL, post-chemo CMR Retrospective, 31 patients Variable ECV regression seen in 13 patients (92% following responsive chemotherapy), ECV correlated with improved LV mass, LA area and diastolic function parameters
Fontana et al, 2020 ATTR, post-patisiran (75% also diflunisal) CMR Retrospective, 16 patients 0, 12 months Significant reduction in ECV (adjusted mean difference −6.2%)

AL: systemic amyloidosis, ATTR: transthyretin amyloidosis, SCT: stem cell transplantation,

#

non-responders and responders = “haematological response to chemotherapy”

IVWT: interventricular wall thickness, SV: stroke volume index, EF: ejection fraction, CI: cardiac index